10 updates for Gynecologic Cancer Awareness Month
September is Gynecologic Cancer Awareness Month, an awareness campaign launched by the Foundation for Women’s Cancer.
SHARE — a nonprofit that supports, educates and empowers women affected by breast or ovarian cancer — is supporting the second year of a social media campaign that encourages patients, survivors and advocates to share their knowledge and experiences using #IWishIKnew on social media.
In collaboration with Foundation for Women’s Cancer, Clearity Foundation, Colorado Ovarian Cancer Alliance, FORCE, Foundation for Women’s Cancer, Sandy Rollman Ovarian Cancer Foundation, Steps Through OC, T.E.A.L. and others, the campaign aims to educate the public about ovarian cancer symptoms, risks and detection options.
To correspond with this campaign, HemOnc Today compiled 10 stories for oncologists on screening recommendations, updates in cancer prevention, health disparities and treatment advances across gynecologic cancers.
- CDC data showed that most of the estimated 34,800 cancers attributed to HPV annually between 2012 and 2016 could have been prevented had the patient received the 9-valent HPV vaccine READ MORE
- The U.S. Preventive Services Task Force recommends that physicians screen women with a familial risk assessment tool if they have family history of breast, ovarian, tubal or peritoneal cancer, or if they have an ancestry associated with BRCA1 or BRCA2 mutations. READ MORE
- Women with cervical cancer who experienced psychiatric disorders and stress around the time of diagnosis demonstrated higher rates of cancer-specific mortality than women without such distress at diagnosis. READ MORE
- Michael J. Birrer, MD, PhD, professor of medicine, OB/GYN and pathology in the division of hematology/oncology at The University of Alabama at Birmingham, discusses in a commentary whether treatment advances and a greater understanding of tumor biology could indicate the “beginning of the end” for ovarian cancer. READ MORE
- Chemoradiotherapy significantly improved OS and failure-free survival compared with pelvic radiotherapy alone among women with high-risk endometrial cancer. READ MORE
- Niraparib (Zejula, Tesaro) demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease. READ MORE
- Incidence of aggressive uterine cancer subtypes has increased rapidly since the turn of the century, with racial disparities reflected in higher rates and shorter survival among black women. READ MORE
- Women who underwent minimally invasive surgery for early-stage cervical cancer demonstrated higher odds of recurrence than women who underwent open surgery. READ MORE
- The addition of radiation to platinum-based chemotherapy did not improve RFS among women with stage III or IVA endometrial cancer. READ MORE
- Olaparib (Lynparza, AstraZeneca) monotherapy significantly improved overall response rates and PFS, with no new safety signals, compared with nonplatinum chemotherapy among women with germline BRCA-mutated, platinum-sensitive relapsed ovarian cancer. READ MORE